VERU INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
VERU INC. (VERU) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $6.00 thousand as of 2023-09-30, per its 10-K/A filed 2024-04-01.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2024-04-01
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $6.00K.
- 2022-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $71.00K.
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $71.00K.
- 2020-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $323.71K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2023-09-30 | $6.00K 10-K/A · filed 2024-04-01 |
| 2022-09-30 | $71.00K 10-K · filed 2022-12-05 |
| 2021-09-30 | $71.00K 10-K · filed 2021-12-02 |
| 2020-09-30 | $323.71K 10-K · filed 2020-12-10 |
| 2019-09-30 | $316.37K 10-K · filed 2019-12-12 |
| 2018-09-30 | $309.23K 10-K · filed 2018-12-13 |
| 2017-09-30 | $275.26K 10-K · filed 2018-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |